scholarly journals Pancreatic acinar cell carcinoma with extension into the main pancreatic duct: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Masato Kayahara ◽  
Ichiro Onishi ◽  
Naoki Makita ◽  
Shunsuke Kano ◽  
Masayoshi Munemoto ◽  
...  

Abstract Background Pancreatic acinar cell carcinoma (PACC) is a rare exocrine malignant tumor. Its widespread intraductal extension into the main pancreatic duct (MPD) is also rare. Case presentation We report the case of a 71-year-old man with PACC with MPD extension. The patient was assessed with laboratory and radiographic investigations that facilitated a preoperative diagnosis. Endoscopic ultrasonography (EUS) and dynamic thin-slice multi-detector row computed tomography (MDCT) were useful for determining the resection line of the pancreas. EUS-guided fine needle aspiration (EUS-FNA) was also helpful in determining the tumor biology and treatment strategy. Distal pancreatectomy was performed. The MPD was occupied by the tumor 35 mm downstream and 5 mm upstream. Histopathologically, the pancreatic tail tumor extended continuously into the MPD. The tumor was solid with cells showing eosinophilic and granular cytoplasm, indicating the diagnosis of PACC. This is an interesting case of PACC with intraductal extension into the MPD. We discuss the possible mechanisms of tumor extension in this rare case together with a review of the literature. Conclusions We describe a rare pancreatic acinar cell carcinoma that could be adequately treated using preoperative precise imaging and histopathological evaluations. When an intraductal tumor extension in the MPD is encountered, the diagnosis of a rare pancreatic tumor should be considered, as in our case.

2010 ◽  
Vol 43 (2) ◽  
pp. 373-378 ◽  
Author(s):  
Mineo Iwatate ◽  
Hiroyuki Matsubayashi ◽  
Keiko Sasaki ◽  
Naoki Kishida ◽  
Shusuke Yoshikawa ◽  
...  

Suizo ◽  
2018 ◽  
Vol 33 (5) ◽  
pp. 799-805
Author(s):  
Yukiko WADA ◽  
Yasuhisa ANDO ◽  
Hironobu SUTO ◽  
Minoru OSHIMA ◽  
Keiichi OKANO ◽  
...  

2007 ◽  
Vol 18 (2) ◽  
pp. 95-102 ◽  
Author(s):  
György Illyés ◽  
Andrea Luczay ◽  
Gábor Benyó ◽  
Attila Kálmán ◽  
Katalin Borka ◽  
...  

2007 ◽  
Vol 106 (8) ◽  
pp. 669-672 ◽  
Author(s):  
Yang-Chao Lin ◽  
Po-Huang Lee ◽  
Yu-Tung Yao ◽  
Jong-Kai Hsiao ◽  
Jin-Chuan Sheu ◽  
...  

1996 ◽  
Vol 3 (1) ◽  
pp. 71-73 ◽  
Author(s):  
Takashi Ohsato ◽  
Ryuichi Mibu ◽  
Eishi Nagai ◽  
Hiroshi Satoh ◽  
Mitsuo Iida ◽  
...  

Suizo ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 270-278
Author(s):  
Taro MASHIKO ◽  
Kohei TAJIMA ◽  
Naoki YAZAWA ◽  
Yoshihito MASUOKA ◽  
Toshio NAKAGOHRI

2021 ◽  
Author(s):  
Jianying Xu ◽  
Wenlong Guan ◽  
Shixun Lu ◽  
Xiaoli Wei ◽  
Wenjie Shi ◽  
...  

Abstract Background: Pancreatic acinar cell carcinoma (PACC) is rare and its appropriate treatment remains unknown dued to limited and selection-biased dataMethods: The data on clinicopathologic characteristics, molecular alteration, treatment and survival of patients diagnosed as PACC in Sun Yat-sen university cancer center from 2005 to 2020 were collected. We explored the optimal treatment by co-analyzing our results and published literatures.Results: 22 PACC patients were enrolled. 8/17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n=3) had better mDFS than those with gemcitabine-based regimen (n=5) (unreached vs. 27 months). 8 metastatic patients received 1st-line chemotherapy. 4/5 patients with FOLFIRINOX regimen achieved partial response (PR) and 3 patients with AG (albumin paclitaxel+gemcitabine) regimen got progressive disease (PD). 4 patients received 2nd-line chemotherapy. 2 patients with FOLFIRINOX regimen achieved PR while 2 patients with AG regimen got PD. One patient who had responded to 1st-line FOLFIRINOX regimen received Olaparib as maintenance treatment for 5 months with good tolerance. 31 published literatures and a total of 86 cases were included in the co-analysis. Objective response rate of 1st-line fluoropyrimidine-based regimen (n=47) was higher than that of gemcitabine-based regimen (n=39) (59.6% vs.15.3%, P<0.001). 8/11 patients treated with FOLFIRINOX regimen achieved PR. Conclusions: The benefit of adjuvant chemotherapy remained unclear; however, fluoropyrimidine-based chemotherapy deserves attention. For metastatic patients, fluorouracil-based regimen such as FOLFIRINOX is preferred, and maintenance treatment of PARP inhibitors after effective platinum-containing treatment for BRAC mutation patients is worthy of exploration.


Sign in / Sign up

Export Citation Format

Share Document